Estrella Immunopharma (ESLA) Operating Income (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Operating Income of -$2.3 million for Q1 2026, down 9.3% year-over-year from -$2.5 million in Q1 2025, and down 275.08% quarter-over-quarter from -$613199.0 in Q4 2025.
Estrella Immunopharma (ESLA) Operating Income (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Operating Income for 6 consecutive years, with -$2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 9.3% year-over-year to -$2.3 million; the TTM figure through Mar 2026 stood at -$13.3 million (up 29.27% YoY), while the FY2025 annual figure was -$13.1 million, down 47.67% from the prior year.
- Operating Income fell to -$2.3 million in Q1 2026 per ESLA's latest filing, from -$613199.0 in the prior quarter.
- Across five years, Operating Income topped out at -$144940.0 in Q1 2022 and bottomed at -$8.4 million in Q1 2023.
- Historically, Operating Income has averaged -$3.1 million across 5 years, with a median of -$2.3 million in 2026.
- Annual changes were most pronounced in 2022 — Operating Income plunged 17597.19% — and 2024, when it jumped 94.4%.
- Estrella Immunopharma's Operating Income stood at -$5.6 million in 2022, then jumped by 81.91% to -$1.0 million in 2023, then slumped by 333.75% to -$4.4 million in 2024, then surged by 86.15% to -$613199.0 in 2025, then tumbled by 275.08% to -$2.3 million in 2026.
- Business Quant data shows ESLA's Operating Income at -$2.3 million in Q1 2026, -$613199.0 in Q4 2025, and -$4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - | -2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.08 Mn |
| Mar 31, 2026 | -2.30 Mn |
| Dec 31, 2025 | -613,199.00 |
| Sep 30, 2025 | -4.80 Mn |
| Jun 30, 2025 | -5.54 Mn |
| Mar 31, 2025 | -2.10 Mn |
| Dec 31, 2024 | -4.43 Mn |
| Sep 30, 2024 | -7.80 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Mar 31, 2024 | -469,530.00 |
| Dec 31, 2023 | -1.02 Mn |
| Sep 30, 2023 | -1.87 Mn |
| Jun 30, 2023 | -318,887.00 |
| Mar 31, 2023 | -8.38 Mn |
| Dec 31, 2022 | -5.64 Mn |
| Sep 30, 2022 | -2.89 Mn |
| Jun 30, 2022 | -423,765.00 |
| Mar 31, 2022 | -144,940.00 |
| Dec 31, 2021 | -136,654.00 |
| Sep 30, 2021 | -108,114.00 |